Rigel Pharmaceuticals (RIGL) Stock Forecast, Price & News

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Rigel Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" RIGL shares.
View RIGL analyst ratings or view top-rated stocks.

4 equities research analysts have issued 12 month price targets for Rigel Pharmaceuticals' stock. Their RIGL share price forecasts range from $2.00 to $15.00. On average, they expect the company's stock price to reach $5.75 in the next year. This suggests a possible upside of 413.4% from the stock's current price.
View analysts price targets for RIGL or view top-rated stocks among Wall Street analysts.

Rigel Pharmaceuticals' stock was trading at $1.50 at the start of the year. Since then, RIGL stock has decreased by 25.3% and is now trading at $1.12.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our RIGL earnings forecast.

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) posted its earnings results on Tuesday, August, 1st. The biotechnology company reported ($0.04) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.08) by $0.04. The biotechnology company had revenue of $26.89 million for the quarter, compared to the consensus estimate of $26.02 million. During the same quarter in the previous year, the company earned ($0.08) earnings per share.

6 employees have rated Rigel Pharmaceuticals Chief Executive Officer Raul Rodriguez on Glassdoor.com. Raul Rodriguez has an approval rating of 84% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Rigel Pharmaceuticals investors own include ADMA Biologics (ADMA), Matinas BioPharma (MTNB), Zosano Pharma (ZSAN), Sorrento Therapeutics (SRNE), Aeterna Zentaris (AEZS), KushCo (KSHB), Novan (NOVN), Bionano Genomics (BNGO), Organigram (OGI) and Pennsylvania Real Estate Investment Trust (PEI).

Rigel Pharmaceuticals trades on the NASDAQ under the ticker symbol "RIGL."

Rigel Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (8.38%), Acadian Asset Management LLC (2.63%), Assenagon Asset Management S.A. (2.09%), State Street Corp (2.02%), Geode Capital Management LLC (1.95%) and Nuveen Asset Management LLC (1.41%). Insiders that own company stock include David A Santos, Dean L Schorno and Raul R Rodriguez.
View institutional ownership trends.

Shares of RIGL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of RIGL stock can currently be purchased for approximately $1.12.

Rigel Pharmaceuticals (NASDAQ:RIGL) has a market capitalization of $195.28 million and generates $120.24 million in revenue each year. The biotechnology company earns $-58,570,000.00 in net income (profit) each year or ($0.22) on an earnings per share basis.

The company employs 155 workers across the globe.

Rigel Pharmaceuticals' mailing address is 1180 VETERANS BOULEVARD, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.rigel.com. The biotechnology company can be reached via phone at (650) 624-1100, via email at ir@rigel.com, or via fax at 650-624-1101.